Boehringer Ingelheim - Digital Transformation Strategies

Boehringer Ingelheim - Digital Transformation Strategies

Summary

This report provides insights into Boehringer’s tech activities, including its digital transformation strategies, its innovation programs, its technology initiatives and investments.

Boehringer is a family-owned pharmaceutical company engaged in the discovery, development, manufacture, and marketing of human pharmaceuticals and animal healthcare products. The company’s human pharmaceuticals product portfolio includes medicines for respiratory diseases, cardiovascular and metabolic diseases, skin diseases, cancer, neurological diseases, and infectious diseases. Its animal healthcare product portfolio includes medicines for pets, horses, swine, cattle/ruminants and poultry. The company sells its products in the Americas, Europe, Asia, Australia and Africa, and its business segments are human pharma, animal health, and biopharmaceutical contract manufacturing.

Scope

• Boehringer is strengthening its focus on the use of key disruptive technologies to enhance its operational efficiency and product offerings. To do so, it is tapping into key disruptive technologies including AI, big data, digital therapeutics, and cloud, among others.
• Boehringer developed a fully customized NLP-driven analytics platform which analyzes and obtains actionable insights from unstructured text sources.
• Boehringer launched its in-house Data Science Academy in partnership with Capgemini in October 2021 to increase the data literacy and expertise of its employees.

Reasons to Buy

• Gain insights into Boehringer's technology initiatives.
• Gain insights into its digital strategies and innovation initiatives.
• Gain insights into its technology themes under focus.
• Gain insights into its various technology launches, partnerships and investments.